Evommune, Inc. (NYSE: EVMN)
Health Care · Biotechnology · US
$6.08
-2.25% today · -69.3% 1Y
Evommune, Inc. (NYSE: EVMN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $225.74M and employs 48 people.
Over the last twelve months the share price has lost 69.3%, trading between 6.08 and 33.20.
Tweenvest scores Evommune, Inc. across four factors: quality 48/100, value 69/100. Its strongest factor is value.
EVMN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $225.74M
- Revenue (TTM)
- $10.00M
- P/E
- —
- EPS
- -4.15
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $33.20
- 52-week low
- $6.08
- Avg volume (3M)
- —
- Shares outstanding
- 36.29M
- Employees
- 48
- Next earnings
- —
About Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
- ISIN
- US30054Y1073
- Founded
- 2020
- Listed since
- Nov 6, 2025
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| InflaRx N.V.NasdaqGS: IFRX | $229.89M | $1.52 | -2.56% |
| Panacea Biotec LimitedNSEI: PANACEABIO | $228.42M | Rs359.05 | -3.64% |
| Lyell Immunopharma, Inc.NasdaqGS: LYEL | $226.92M | $8.25 | -10.91% |
| MacroGenics, Inc.NasdaqGS: MGNX | $226.14M | $3.48 | -1.97% |
| Keros Therapeutics, Inc.NasdaqGM: KROS | $225.24M | $11.12 | -2.11% |
| HansBiomed CorporationKOSDAQ: A042520 | $225.02M | ₩21,250.00 | +19.52% |
| Beijing Biostar Pharmaceuticals Co., Ltd.SEHK: 2563 | $224.41M | HK$4.83 | +13.65% |
| Cartesian Therapeutics, Inc.NasdaqGM: RNAC | $222.68M | $6.60 | -10.33% |
Figures last refreshed Oct 4, 2026.